Popular Articles

Orszag, Sebelius And Emanuel Take Lead Roles In Health Debate
Various news outlets examined the powerful roles members of the Obama administration are taking in the health care debate.

In Joint Statement, Industry Groups Reiterate Commitment To Reduce Health Spending Growth
The six industry groups that pledged to reduce health care spending growth by $2 trillion over 10 years on Friday issued a statement reaffirming their commitment to work toward the goal, Roll Call reports (Murray, Roll Call, 5/15). The industry groups in a letter sent to President Obama on May 10 wrote, "We will do our part to achieve your administration"s goal of decreasing by 1.5 percentage points the annual health care spending growth rate. ... This represents more than a 20% reduction in the projected rate of growth." The letter -- which was signed by the American Medical Association, the American Hospital Association, Pharmaceutical Research and Manufacturers of America, the Advanced Medical Technology Association, America"s Health Insurance Plans and the Service Employees International Union -- did not elaborate on what specific measures the groups would take to achieve such reductions (Kaiser Daily Health Policy Report, 5/12). Obama in a May 11 public announcement of the groups" pledge said the coalition"s goal was to cut the growth rate by 1.5 percentage points "each year," which would total $2 trillion over 10 years (Norman, CQ HealthBeat, 5/15).However, industry leaders who attended the meeting with Obama said that they did not promise specific year-by-year savings, but instead agreed to a more incremental approach (Kaiser Daily Health Policy Report, 5/15). Richard Umbdenstock, president of AHA, said, "There"s been a lot of misunderstanding that has caused a lot of consternation among our members." AHA sent its members a bulletin stating that "the groups did not support reducing the rate of health spending by 1.5 percentage points annually," and that the pledge was to eventually reduce the growth rate by 1.5 percentage points (CQ HealthBeat, 5/15).In response to media reports that said they were backing away from their pledge, the groups on Friday in a joint statement reiterated their vow. They wrote, "Our organizations are currently engaged in an intensive process to develop proposals to reduce the rate of increase in future health care costs" (Young, The Hill, 5/15). The statement also said, "We are committed to working together to bend the health care cost curve" and "to doing our part to make reform sustainable and to make the system more affordable and effective for patients and purchasers" (Budoff Brown, Politico, 5/18). It continued that "to be successful, we must take action in public-private partnership. We look forward to offering cost-savings recommendations in the weeks ahead." The Obama administration has requested specifics on the coalition"s cost-cutting plans by June 1. White House Office of Management and Budget Director Peter Orszag on Friday in a blog post wrote that it is "understandable" that the groups need to "ramp up" to the 1.5 percentage point reduction in spending. According to Orszag, "The groups have committed to significant reductions in the growth rate, thereby recognizing that substantial efficiencies can be captured in the health system. Some ramp-up time also does not materially affect the long-term impact from reducing the growth rate, on either national health expenditures or the federal budget" (CQ HealthBeat, 5/15). Orszag"s blog posting is available online.
News of the day
Cigarette Packaging Still Misleading Consumers Over Health Hazards
New research suggests that current regulations have failed to remove misleading information from cigarette packaging, revealing that a substantial majority of consumers believe cigarettes are less hazardous when the packs display words such as "silver" or "smooth," lower numbers incorporated into the brand name, lighter colours or pictures of filters.
Oncology

ActoGeniX Obtains IND Approval

ActoGeniX, a development stage biopharmaceutical company, announced that the United States÷´ Food and Drug Administration (FDA) has approved the Company÷´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX÷´s portfolio. Oral mucositis is a painful inflammation of the oral mucosa affecting cancer patients and making daily activities such as eating, drinking and talking difficult or impossible. It is a severe and debilitating disease for which no effective cure is available today. AG013 is based on ActoGeniX÷´s proprietary TopAct™ platform and constitutes of an oral rinsing solution that delivers a potent healing factor to the damaged mucosa in the oral cavity. In preclinical pharmacology studies AG013 has already shown significant efficacy results suggesting that it holds great promise for the treatment of oral mucositis in cancer patients. ActoGeniX÷´s phase 1B clinical study will be conducted in six major oncology centers in the US, and will mainly evaluate safety and tolerability of the new product, but will also allow the collection of efficacy data. 21 Patients will be included in this placebo-controlled, single blinded, dose escalation study, which is expected to be completed during the first half of 2010. Dr. Mark Vaeck, CEO of ActoGeniX, commented: "We are extremely pleased with this approval by the FDA, which is a clear endorsement of the quality of our preclinical data package and development plan for AG013. Oral mucositis is a very significant and underserved opportunity in the cancer supportive care market, and a novel therapeutic product in this area has huge commercial potential." Dr. Bernard Coulie, Chief Medical Officer of ActoGeniX, added: "With the advancement into clinical development of AG013, our second lead product, ActoGeniX is well on its way to effectively build a significant clinical-stage product pipeline. Moreover AG013 could become the first approved therapy for oral mucositis in patients undergoing treatment of solid tumors or head/neck cancers." About Oral mucositis Oral mucositis is the (painful) inflammation, necrosis and ulceration of the oral mucosa, affecting nearly every patient that receives radiotherapy of the head/neck region or bone marrow transplant and a large proportion of solid tumor patients treated with chemotherapy or radiation therapy. Cardinal symptoms include ulcerations, debilitating pain and inability to eat and/or sustain anti-cancer therapy. Every year approximately 4 million new cases of cancer are diagnosed in the Western World, and almost 50% of those will develop oral mucositis. The economical costs due to oral mucositis are substantial, driven by the required additional medical care and extended hospital stay. ActoGeniX


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):